
NATURE . COM {
}
Title:
Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy | Nature Communications
Description:
Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
Website Age:
30 years and 10 months (reg. 1994-08-11).
Matching Content Categories {📚}
- Science
- Education
- Sports
Content Management System {📝}
What CMS is nature.com built with?
Custom-built
No common CMS systems were detected on Nature.com, and no known web development framework was identified.
Traffic Estimate {📈}
What is the average monthly size of nature.com audience?
🌆 Monumental Traffic: 20M - 50M visitors per month
Based on our best estimate, this website will receive around 42,554,915 visitors per month in the current month.
check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush
How Does Nature.com Make Money? {💸}
Display Ads {🎯}
The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.
Ads are managed by yourbow.com. Particular relationships are as follows:
Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.comReseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.comHow Much Does Nature.com Make? {💰}
Display Ads {🎯}
$536,300 per month
According to our algorithms, Nature.com's monthly online income from display advertising ranges from $357,503 to $983,134.
Keywords {🔍}
cells, ball, cell, article, cart, therapy, fig, cdneg, google, scholar, tcdneg, supplementary, nature, expression, analysis, relapse, clusters, cas, data, leukemia, samples, acute, clones, tcdpos, pcr, antigen, lymphoblastic, mrna, singlecell, cancer, patient, leukemic, gene, cdna, genes, scrnaseq, med, chimeric, patients, anticd, treatment, car, tumoral, performed, information, study, genomics, umap, expressed, facs,
Topics {✒️}
org/cistarget/databases/homo_sapiens/hg19/refseq_r45/mc9nr/gene_based/hg19-tss-centered-10kb-7species hg19-tss-centered-10kb-7species nature portfolio org/record/4114854/files/refdata-cellranger-grch38-3 /supp/cell-exp/refdata-cellranger-grch38-3 privacy policy middle facs plots distinct anti-cd45-hashtag oligonucleotide advertising click chemistry tools social media regional council mrna library reads water 10 mm tco-peg4-nhs nature 545 nature specific anti-cd45-hto antibody future research reprints single-cell rna sequencing single-cell rna-sequencing acute lymphoblastic leukaemia libraries sequencing chimeric antigen receptor–modified research design research funding horizon 2020 research b-acute lymphoblastic leukemia bulk rna-sequencing data single-cell cdna synthesis dominique payet-bornet b-cell lymphoblastic leukemia express full-length transcripts 10 mm tco-peg4-nhs cancer-related childhood mortality1 investigate large-scale cnv peer review reports acute lymphoblastic leukemia 1 mm mtz-peg4-nhs evade cd19-targeted therapy cd19-negative relapse permitting de la sant� original author permissions chimeric antigen receptor libraries single-cell data escape car-mediated recognition /hoohm/cite-seq-count chimeric antigen receptors
Questions {❓}
- Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
- Gov/sra?
Schema {🗺️}
WebPage:
mainEntity:
headline:Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
description:Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
datePublished:2021-02-08T00:00:00Z
dateModified:2021-02-08T00:00:00Z
pageStart:1
pageEnd:7
license:http://creativecommons.org/licenses/by/4.0/
sameAs:https://doi.org/10.1038/s41467-021-21168-6
keywords:
Acute lymphocytic leukaemia
Cancer immunotherapy
Science
Humanities and Social Sciences
multidisciplinary
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig2_HTML.png
isPartOf:
name:Nature Communications
issn:
2041-1723
volumeNumber:12
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Tracy Rabilloud
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Delphine Potier
url:http://orcid.org/0000-0003-1684-9888
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Saran Pankaew
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Mathis Nozais
url:http://orcid.org/0000-0001-8114-904X
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Marie Loosveld
url:http://orcid.org/0000-0002-8372-4148
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Laboratoire dâHématologie
address:
name:APHM, Hôpital La Timone, Laboratoire dâHématologie, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Dominique Payet-Bornet
url:http://orcid.org/0000-0003-3196-3814
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
type:ScholarlyArticle
context:https://schema.org
ScholarlyArticle:
headline:Single-cell profiling identifies pre-existing CD19-negative subclones in a B-ALL patient with CD19-negative relapse after CAR-T therapy
description:Chimeric antigen receptor T cell (CAR-T) targeting the CD19 antigen represents an innovative therapeutic approach to improve the outcome of relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Yet, despite a high initial remission rate, CAR-T therapy ultimately fails for some patients. Notably, around half of relapsing patients develop CD19 negative (CD19neg) B-ALL allowing leukemic cells to evade CD19-targeted therapy. Herein, we investigate leukemic cells of a relapsing B-ALL patient, at two-time points: before (T1) and after (T2) anti-CD19 CAR-T treatment. We show that at T2, the B-ALL relapse is CD19 negative due to the expression of a non-functional CD19 transcript retaining intron 2. Then, using single-cell RNA sequencing (scRNAseq) approach, we demonstrate that CD19neg leukemic cells were present before CAR-T cell therapy and thus that the relapse results from the selection of these rare CD19neg B-ALL clones. In conclusion, our study shows that scRNAseq profiling can reveal pre-existing CD19neg subclones, raising the possibility to assess the risk of targeted therapy failure. CD19-negative relapses are observed in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with anti-CD19 CAR-T cells. Here, by single-cell RNA sequencing of leukemic cells in a patient with B-ALL, the authors show that pre-existing CD19 negative leukemic subclones are present before CAR-T cell therapy and can account for the relapse.
datePublished:2021-02-08T00:00:00Z
dateModified:2021-02-08T00:00:00Z
pageStart:1
pageEnd:7
license:http://creativecommons.org/licenses/by/4.0/
sameAs:https://doi.org/10.1038/s41467-021-21168-6
keywords:
Acute lymphocytic leukaemia
Cancer immunotherapy
Science
Humanities and Social Sciences
multidisciplinary
image:
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig1_HTML.png
https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_Fig2_HTML.png
isPartOf:
name:Nature Communications
issn:
2041-1723
volumeNumber:12
type:
Periodical
PublicationVolume
publisher:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
type:Organization
author:
name:Tracy Rabilloud
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Delphine Potier
url:http://orcid.org/0000-0003-1684-9888
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Saran Pankaew
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Mathis Nozais
url:http://orcid.org/0000-0001-8114-904X
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
type:Person
name:Marie Loosveld
url:http://orcid.org/0000-0002-8372-4148
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Laboratoire dâHématologie
address:
name:APHM, Hôpital La Timone, Laboratoire dâHématologie, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
type:Person
name:Dominique Payet-Bornet
url:http://orcid.org/0000-0003-3196-3814
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
type:Person
isAccessibleForFree:1
["Periodical","PublicationVolume"]:
name:Nature Communications
issn:
2041-1723
volumeNumber:12
Organization:
name:Nature Publishing Group UK
logo:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
type:ImageObject
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
name:Laboratoire dâHématologie
address:
name:APHM, Hôpital La Timone, Laboratoire dâHématologie, Marseille, France
type:PostalAddress
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
ImageObject:
url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
name:Tracy Rabilloud
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Delphine Potier
url:http://orcid.org/0000-0003-1684-9888
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Saran Pankaew
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Mathis Nozais
url:http://orcid.org/0000-0001-8114-904X
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Marie Loosveld
url:http://orcid.org/0000-0002-8372-4148
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
name:Laboratoire dâHématologie
address:
name:APHM, Hôpital La Timone, Laboratoire dâHématologie, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
name:Dominique Payet-Bornet
url:http://orcid.org/0000-0003-3196-3814
affiliation:
name:CIML
address:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
type:PostalAddress
type:Organization
email:[email protected]
PostalAddress:
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
name:APHM, Hôpital La Timone, Laboratoire dâHématologie, Marseille, France
name:Aix Marseille Université, CNRS, INSERM, CIML, Marseille, France
Social Networks {👍}(2)
External Links {🔗}(101)
- https://orcid.org/0000-0003-1684-9888 income
- How much does https://orcid.org/0000-0001-8114-904X pull in?
- How much does https://orcid.org/0000-0002-8372-4148 pull in?
- Monthly income for https://orcid.org/0000-0003-3196-3814
- Revenue of http://www.cite-seq.com
- What's the financial gain of https://github.com/Hoohm/CITE-seq-Count?
- What's the monthly money flow for https://www.ncbi.nlm.nih.gov/sra?term=SRP269742?
- Find out how much https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE153697 earns monthly
- What's the monthly income of https://cf.10xgenomics.com/supp/cell-exp/refdata-cellranger-GRCh38-3.0.0.tar.gz?
- Explore the financials of https://zenodo.org/record/4114854/files/refdata-cellranger-GRCh38-3.0.0.tar.gz?download=1
- Find out how much https://resources.aertslab.org/cistarget/databases/homo_sapiens/hg19/refseq_r45/mc9nr/gene_based/hg19-tss-centered-10kb-7species.mc9nr.feather earns monthly
- How much profit does https://doi.org/10.5281/zenodo.4114854 generate?
- https://github.com/Delphine-Potier/B-ALL-CAR-T income
- How much revenue does https://doi.org/10.1056%2FNEJMra1400972 produce monthly?
- Monthly income for http://scholar.google.com/scholar_lookup?&title=Acute%20lymphoblastic%20leukemia%20in%20children&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMra1400972&volume=373&pages=1541-1552&publication_year=2015&author=Hunger%2CSP&author=Mullighan%2CCG
- What's the monthly income of https://doi.org/10.1016%2Fj.bbmt.2018.12.068?
- How much cash flow does http://scholar.google.com/scholar_lookup?&title=Clinical%20utilization%20of%20chimeric%20antigen%20receptor%20T%20cells%20in%20B%20cell%20acute%20lymphoblastic%20leukemia%3A%20an%20expert%20opinion%20from%20the%20european%20society%20for%20blood%20and%20marrow%20transplantation%20and%20the%20american%20society%20for%20transplantation%20and%20cellular%20therapy&journal=Biol.%20Blood%20Marrow%20Transplant.&doi=10.1016%2Fj.bbmt.2018.12.068&volume=25&pages=e76-e85&publication_year=2019&author=Kansagra%2CAJ have monthly?
- https://doi.org/10.1126%2Fscitranslmed.3005930's revenue stream
- Monthly income for http://scholar.google.com/scholar_lookup?&title=CD19-targeted%20T%20cells%20rapidly%20induce%20molecular%20remissions%20in%20adults%20with%20chemotherapy-refractory%20acute%20lymphoblastic%20leukemia&journal=Sci.%20Transl.%20Med.&doi=10.1126%2Fscitranslmed.3005930&volume=5&publication_year=2013&author=Brentjens%2CRJ
- How much revenue does https://doi.org/10.1126%2Fscitranslmed.aac5415 bring in?
- How much does http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%20T%20cells%20persist%20and%20induce%20sustained%20remissions%20in%20relapsed%20refractory%20chronic%20lymphocytic%20leukemia&journal=Sci.%20Transl.%20Med.&doi=10.1126%2Fscitranslmed.aac5415&volume=7&publication_year=2015&author=Porter%2CDL pull in?
- How much cash flow does https://doi.org/10.1056%2FNEJMoa1215134 have monthly?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%E2%80%93modified%20T%20cells%20for%20acute%20lymphoid%20leukemia&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1215134&volume=368&pages=1509-1518&publication_year=2013&author=Grupp%2CSA?
- How much does https://doi.org/10.1038%2Fnature22395 net monthly?
- How much does http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2017Natur.545..423S make?
- http://scholar.google.com/scholar_lookup?&title=Therapeutic%20T%20cell%20engineering&journal=Nature&doi=10.1038%2Fnature22395&volume=545&pages=423-431&publication_year=2017&author=Sadelain%2CM&author=Rivi%C3%A8re%2CI&author=Riddell%2CS's total income per month
- Income figures for https://doi.org/10.1056%2FNEJMoa1709866
- How much income does http://scholar.google.com/scholar_lookup?&title=Tisagenlecleucel%20in%20children%20and%20young%20adults%20with%20B-cell%20lymphoblastic%20leukemia&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1709866&volume=378&pages=439-448&publication_year=2018&author=Maude%2CSL have?
- https://doi.org/10.1182%2Fblood-2017-02-769208's revenue stream
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Intent-to-treat%20leukemia%20remission%20by%20CD19%20CAR%20T%20cells%20of%20defined%20formulation%20and%20dose%20in%20children%20and%20young%20adults&journal=Blood&doi=10.1182%2Fblood-2017-02-769208&volume=129&pages=3322-3331&publication_year=2017&author=Gardner%2CRA?
- How much does https://doi.org/10.1126%2Fscitranslmed.3008226 make?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Efficacy%20and%20toxicity%20management%20of%2019-28z%20CAR%20T%20cell%20therapy%20in%20B%20cell%20acute%20lymphoblastic%20leukemia&journal=Sci.%20Transl.%20Med.&doi=10.1126%2Fscitranslmed.3008226&volume=6&pages=224ra25-224ra25&publication_year=2014&author=Davila%2CML?
- How much income does https://doi.org/10.1016%2FS0140-6736%2814%2961403-3 have?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=T%20cells%20expressing%20CD19%20chimeric%20antigen%20receptors%20for%20acute%20lymphoblastic%20leukaemia%20in%20children%20and%20young%20adults%3A%20a%20phase%201%20dose-escalation%20trial&journal=Lancet&doi=10.1016%2FS0140-6736%2814%2961403-3&volume=385&pages=517-528&publication_year=2015&author=Lee%2CDW generate?
- Financial intake of https://doi.org/10.1056%2FNEJMoa1709919
- What's the revenue for http://scholar.google.com/scholar_lookup?&title=Long-term%20follow-up%20of%20CD19%20CAR%20therapy%20in%20acute%20lymphoblastic%20leukemia&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1709919&volume=378&pages=449-459&publication_year=2018&author=Park%2CJH?
- Financial intake of https://doi.org/10.1056%2FNEJMoa1407222
- What is the earnings of http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%20T%20cells%20for%20sustained%20remissions%20in%20leukemia&journal=N.%20Engl.%20J.%20Med.&doi=10.1056%2FNEJMoa1407222&volume=371&pages=1507-1517&publication_year=2014&author=Maude%2CSL?
- How much revenue does https://doi.org/10.3389%2Ffonc.2020.01594 bring in?
- How much does http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%20T-cells%20in%20B-acute%20lymphoblastic%20leukemia%3A%20state%20of%20the%20art%20and%20future%20directions&journal=Front.%20Oncol.&doi=10.3389%2Ffonc.2020.01594&volume=10&publication_year=2020&author=Greenbaum%2CU&author=Mahadeo%2CKM&author=Kebriaei%2CP&author=Shpall%2CEJ&author=Saini%2CNY pull in monthly?
- Check the income stats for https://doi.org/10.3389%2Ffimmu.2020.01985
- Income figures for http://scholar.google.com/scholar_lookup?&title=Chimeric%20antigen%20receptor%20T%20cell%20therapy%20for%20pediatric%20B-ALL%3A%20narrowing%20the%20gap%20between%20early%20and%20long-term%20outcomes&journal=Front.%20Immunol.&doi=10.3389%2Ffimmu.2020.01985&volume=11&publication_year=2020&author=Schultz%2CL
- Profit of https://doi.org/10.1038%2Fs41591-018-0146-z
- How much profit is http://scholar.google.com/scholar_lookup?&title=Genetic%20mechanisms%20of%20target%20antigen%20loss%20in%20CAR19%20therapy%20of%20acute%20lymphoblastic%20leukemia&journal=Nat.%20Med.&doi=10.1038%2Fs41591-018-0146-z&volume=24&pages=1504-1506&publication_year=2018&author=Orlando%2CEJ making per month?
- How much profit is https://doi.org/10.1097%2FCJI.0000000000000169 making per month?
- How much money does http://scholar.google.com/scholar_lookup?&title=CD19%20isoforms%20enabling%20resistance%20to%20CART-19%20immunotherapy%20are%20expressed%20in%20B-ALL%20patients%20at%20initial%20diagnosis&journal=J.%20Immunother.&doi=10.1097%2FCJI.0000000000000169&volume=40&pages=187-195&publication_year=2017&author=Fischer%2CJ make?
- Monthly income for https://doi.org/10.1038%2Fs41375-019-0580-z
- Financial intake of http://scholar.google.com/scholar_lookup?&title=Retention%20of%20CD19%20intron%202%20contributes%20to%20CART-19%20resistance%20in%20leukemias%20with%20subclonal%20frameshift%20mutations%20in%20CD19&journal=Leukemia&doi=10.1038%2Fs41375-019-0580-z&volume=34&pages=1202-1207&publication_year=2020&author=Asnani%2CM
- What's the financial intake of https://doi.org/10.1158%2F2159-8290.CD-15-1020?
- How much money does http://scholar.google.com/scholar_lookup?&title=Convergence%20of%20acquired%20mutations%20and%20alternative%20splicing%20of%20CD19%20enables%20resistance%20to%20CART-19%20immunotherapy&journal=Cancer%20Discov.&doi=10.1158%2F2159-8290.CD-15-1020&volume=5&pages=1282-1295&publication_year=2015&author=Sotillo%2CE make?
- What is the earnings of https://link.springer.com/doi/10.1186/s13059-018-1603-1?
- How much does http://scholar.google.com/scholar_lookup?&title=Cell%20Hashing%20with%20barcoded%20antibodies%20enables%20multiplexing%20and%20doublet%20detection%20for%20single%20cell%20genomics&journal=Genome%20Biol.&doi=10.1186%2Fs13059-018-1603-1&volume=19&publication_year=2018&author=Stoeckius%2CM gross monthly?
- How much does https://doi.org/10.1038%2Fncomms14049 gross monthly?
- http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2017NatCo...814049Z's revenue stream
- How much profit does http://scholar.google.com/scholar_lookup?&title=Massively%20parallel%20digital%20transcriptional%20profiling%20of%20single%20cells&journal=Nat.%20Commun.&doi=10.1038%2Fncomms14049&volume=8&publication_year=2017&author=Zheng%2CGXY generate?
- https://doi.org/10.1038%2Fnbt.4096's revenue stream
- How much income does http://scholar.google.com/scholar_lookup?&title=Integrating%20single-cell%20transcriptomic%20data%20across%20different%20conditions%2C%20technologies%2C%20and%20species&journal=Nat.%20Biotechnol.&doi=10.1038%2Fnbt.4096&volume=36&pages=411-420&publication_year=2018&author=Butler%2CA&author=Hoffman%2CP&author=Smibert%2CP&author=Papalexi%2CE&author=Satija%2CR have?
- How much does https://doi.org/10.1038%2Fs41467-019-13779-x generate monthly?
- How much profit does http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2020NatCo..11...89S generate?
- What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=CaSpER%20identifies%20and%20visualizes%20CNV%20events%20by%20integrative%20analysis%20of%20single-cell%20or%20bulk%20RNA-sequencing%20data&journal=Nat.%20Commun.&doi=10.1038%2Fs41467-019-13779-x&volume=11&publication_year=2020&author=Serin%20Harmanci%2CA&author=Harmanci%2CAO&author=Zhou%2CX?
- How much does https://doi.org/10.1126%2Fscience.1066326 gross monthly?
- Get to know http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2001Sci...294.2563N's earnings
- Income figures for http://scholar.google.com/scholar_lookup?&title=KLF6%2C%20a%20candidate%20tumor%20suppressor%20gene%20mutated%20in%20prostate%20cancer&journal=Science&doi=10.1126%2Fscience.1066326&volume=294&pages=2563-2566&publication_year=2001&author=Narla%2CG
- How much cash flow does https://doi.org/10.1038%2Fnrc3582 have monthly?
- What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Kr%C3%BCppel-like%20factors%20in%20cancer&journal=Nat.%20Rev.%20Cancer&doi=10.1038%2Fnrc3582&volume=13&pages=701-713&publication_year=2013&author=Tetreault%2CM-P&author=Yang%2CY&author=Katz%2CJP?
- How much does https://doi.org/10.1038%2Fsrep22675 pull in monthly?
- What's the financial gain of http://adsabs.harvard.edu/cgi-bin/nph-data_query?link_type=ABSTRACT&bibcode=2016NatSR...622675V?
- How much revenue does http://scholar.google.com/scholar_lookup?&title=A%20covalent%20and%20cleavable%20antibody-DNA%20conjugation%20strategy%20for%20sensitive%20protein%20detection%20via%20immuno-PCR&journal=Sci.%20Rep.&doi=10.1038%2Fsrep22675&volume=6&publication_year=2016&author=Buggenum%2CJAGL bring in?
- How much money does https://doi.org/10.1016%2Fj.cell.2019.05.031 generate?
- How profitable is http://scholar.google.com/scholar_lookup?&title=Comprehensive%20integration%20of%20single-cell%20data&journal=Cell&doi=10.1016%2Fj.cell.2019.05.031&volume=177&pages=1888-1902.e21&publication_year=2019&author=Stuart%2CT?
- How much income is https://doi.org/10.1038%2Fnmeth.4463 earning monthly?
- Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=SCENIC%3A%20single-cell%20regulatory%20network%20inference%20and%20clustering&journal=Nat.%20Methods&doi=10.1038%2Fnmeth.4463&volume=14&pages=1083-1086&publication_year=2017&author=Aibar%2CS
- How much does https://citation-needed.springer.com/v2/references/10.1038/s41467-021-21168-6?format=refman&flavour=references net monthly?
- What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Tracy%20Rabilloud?
- What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Tracy%20Rabilloud%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Delphine%20Potier?
- https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Delphine%20Potier%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
- How much money does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Saran%20Pankaew make?
- Find out how much https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Saran%20Pankaew%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earns monthly
- How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Mathis%20Nozais bring in each month?
- What's https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Mathis%20Nozais%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's gross income?
- Explore the financials of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Marie%20Loosveld
- Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Marie%20Loosveld%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- What is the monthly revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Dominique%20Payet-Bornet?
- Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Dominique%20Payet-Bornet%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
- Learn how profitable https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_MOESM1_ESM.pdf is on a monthly basis
- What's the monthly money flow for https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_MOESM2_ESM.pdf?
- How much does https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-021-21168-6/MediaObjects/41467_2021_21168_MOESM3_ESM.pdf generate monthly?
- Profit of http://creativecommons.org/licenses/by/4.0/
- What are the total earnings of https://s100.copyright.com/AppDispatchServlet?title=Single-cell%20profiling%20identifies%20pre-existing%20CD19-negative%20subclones%20in%20a%20B-ALL%20patient%20with%20CD19-negative%20relapse%20after%20CAR-T%20therapy&author=Tracy%20Rabilloud%20et%20al&contentID=10.1038%2Fs41467-021-21168-6©right=The%20Author%28s%29&publication=2041-1723&publicationDate=2021-02-08&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY?
- What's the monthly income of https://crossmark.crossref.org/dialog/?doi=10.1038/s41467-021-21168-6?
- Get to know what's the income of https://citation-needed.springer.com/v2/references/10.1038/s41467-021-21168-6?format=refman&flavour=citation
- What's the income generated by https://doi.org/10.1186/s12943-025-02334-6 each month?
- How much does https://doi.org/10.1038/s41375-024-02449-7 rake in every month?
- How much income is https://doi.org/10.1007/s10555-025-10261-7 earning monthly?
- What are the earnings of https://doi.org/10.1007/s10555-024-10232-4?
- How much does https://doi.org/10.1038/s41467-025-58868-2 bring in each month?
- Check the income stats for https://www.protocols.io/
- Discover the revenue of https://www.natureindex.com/
- What's the income of http://www.naturechina.com?
- What are the total earnings of https://www.natureasia.com/ja-jp?
Analytics and Tracking {📊}
- Google Tag Manager
Libraries {📚}
- Prism.js
- Zoom.js
Emails and Hosting {✉️}
Mail Servers:
- mxa-002c5801.gslb.pphosted.com
- mxb-002c5801.gslb.pphosted.com
Name Servers:
- pdns1.ultradns.net
- pdns2.ultradns.net
- pdns3.ultradns.org
- pdns4.ultradns.org
- pdns5.ultradns.info
- pdns6.ultradns.co.uk
CDN Services {📦}
- Crossref